Ghent University Academic Bibliography

Journal Article
A1
open access

A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia

Igor Fijalkowski (UGent) , Jin Wang, Qi Jin, Jolien Van Laere (UGent) , Valentina Serafin, John D. Crispino and Panagiotis Ntziachristos (UGent)

(2024) LEUKEMIA. 38(1). p.193-197

Add to list

Journal Article
A1
open access

Long-term health-related quality of life in head and neck cancer survivors : a large multinational study

Katherine J. Taylor, Cecilie D. Amdal, Kristin Bjordal, Guro L. Astrup, Bente B. Herlofson, Fréderic Duprez (UGent) , Ricardo R. Gama, Alexandre Jacinto, Eva Hammerlid, Melissa Scricciolo, et al.

(2024) INTERNATIONAL JOURNAL OF CANCER. 154(10). p.1772-1785

Add to list

Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab

Chrisann Kyi, Marloes Van Dongen, Sylvie Rottey (UGent) , Ignacio Melero Bermejo, Diana Mittag, Dane Gouveia, Kees Bol, Chris Yan, Andrew K. Joe, Gianluca Laus, et al.

(2024) JOURNAL OF CLINICAL ONCOLOGY. In Journal of Clinical Oncology 42(16, Supplement S).

Add to list

Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)

Rahul Raj Aggarwal, Sylvie Rottey (UGent) , Alice Bernard-Tessier, Begona Mellado-Gonzalez, Takeo Kosaka, Walter Michael Stadler, Shahneen Sandhu, Brian Yu, Crystal Shaw, Chia-Hsin Ju, et al.

(2024) JOURNAL OF CLINICAL ONCOLOGY. In Journal of Clinical Oncology 42(16, Supplement S).

Add to list

Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+oropharyngeal cancer that progressed with prior anti-PD-1 therapy

A. Kong, C. Even, B. Aguilera, M. Klein Hesselink, S. Visscher, C. H. Chung, J. C. Park, D. R. Adkins, S. Salas, K. J. Harrington, et al.

(2024) ANNALS OF ONCOLOGY. In Annals of Oncology 35(Supplement 2). p.S627-S628

Add to list

Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

C. Friedman, A. De Burgh Williams, J. S. Lopez, K. Ouali, M. R. Middleton, F. Thistlethwaite, O. Hamid, B. Izar, V. Moreno Garcia, M. L. Johnson, et al.

(2024) ANNALS OF ONCOLOGY. In Annals of Oncology 35(Supplement 2). p.S569-S570

Add to list

Inference failure with synthetic arms : empirical application to phase III oncology trials

Alexander Decruyenaere (UGent) , Heidelinde Dehaene (UGent) , Paloma Rabaey (UGent) , Charles Polet (UGent) , Johan Decruyenaere (UGent) , Toon Demeester (UGent) , Stijn Vansteelandt (UGent) and Sylvie Rottey (UGent)

(2024) ANNALS OF ONCOLOGY. In Annals of Oncology 35(Supplement 2). p.S526-S527

Add to list

Journal Article
A1
open access

Improving completion rates of patient-reported outcome measures in cancer clinical trials : scoping review investigating the implications for trial designs

Lotte van der Weijst, Abigirl Machingura, Ahu Alanya, Emma Lidington, Galina Velikova, Hans-Henning Flechtner, Heike Schmidt, Jens Lehmann, John K. Ramage, Jolie Ringash, et al.

(2024) EUROPEAN JOURNAL OF CANCER. 212.

Add to list

Miscellaneous
open access

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nufel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2024) CANCER IMMUNOLOGY IMMUNOTHERAPY. 74(1).

Add to list

Journal Article
A1
open access

Radiotherapy in cutaneous lymphomas : recommendations from the EORTC cutaneous lymphoma tumour group

Khaled Elsayad, Emmanuella Guenova, Chalid Assaf, Jan P. Nicolay, Franz Trautinger, Rudolf Stadler, Cora Waldstein, Tom Boterberg (UGent) , Paul Meijnders, Youlia Kirova, et al.

(2024) EUROPEAN JOURNAL OF CANCER. 212.

Academic Bibliography

A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia

Long-term health-related quality of life in head and neck cancer survivors : a large multinational study

Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab

Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)

Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+oropharyngeal cancer that progressed with prior anti-PD-1 therapy

Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

Inference failure with synthetic arms : empirical application to phase III oncology trials

Improving completion rates of patient-reported outcome measures in cancer clinical trials : scoping review investigating the implications for trial designs

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Radiotherapy in cutaneous lymphomas : recommendations from the EORTC cutaneous lymphoma tumour group

Contents

Support

Contact